Loading clinical trials...

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection | Clinical Trials | Clareo Health

UNKNOWNNA

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

Conventional Therapy vs Sequential Therapy for the Treatment of Helicobacter Pylori Infection

NCT01723059•Dallas VA Medical Center

Summary

Traditionally, H pylori infection has been treated with conventional triple therapy. This includes amoxicillin, clarithromycin and a proton pump inhibitor all given daily for 10-14 days. In Europe, the guidelines now advocate treatment of H pylori with sequential therapy which is 5 days of amoxicillin therapy with proton pump inhibitor followed by 5 days of clarithromycin, metronidazole, and proton pump inhibitor with better response rates. We hypothesize that H. pylori resistance pattern and treatment response rates observed in Europe will not be predictive of resistance patterns and response rates in the United States.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subject has signed informed consent Subject is an adult older than 18 yrs old and requires an upper endoscopic evaluation If female and of child bearing potential, subject has a negative pregnancy test and is not nursing.
•Patient has not received prior treatment for H pylori Subject is able to understand and comply with study procedures

Exclusion Criteria

•Recent use (within 4 weeks) of any of the medications used in the treatment of H pylori(Amoxicillin, Clarithromycin, Metronidazole) Subject undergoing endoscopy for acute gastrointestinal bleeding Subject has an allergy to any of the medications used in the treatment of H pylori Subject has a history of esophageal or gastric carcinoma including lymphoma Subject has esophageal varices or undergoing endoscopy for esophageal banding Subject is taking warfarin or clopidogrel Subject has coagulopathy that precludes safe biopsy of the biopsy areas Subject has comorbidity that precludes safe participation in the study Subject is a pregnant female Subject has a history of H. pylori infection. Patient is already enrolled in GI Study. History of UGI surgery other than Nissen Fundoplication

Locations (1)

Dallas VAMC

Dallas, Texas, United States

Key Dates

Start Date

February 1, 2012

Primary Completion Date

January 1, 2013

Completion Date

January 1, 2013

Last Updated

November 7, 2012

Enrollment

184

ESTIMATED participants

Conditions

Helicobacter Infection

Interventions

Standard Triple Therapy

DRUG

Sequential Therapy

DRUG

Contacts

Byron Cryer, MD

CONTACT

214-857-1603 byron.cryer@utsouthwestern.edu

Elizabeth Coss, MD

CONTACT

817-896-7030 elizabeth.coss@phhs.org

Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

NCT07293910

HELICOBACTER PYLORI INFECTIONSHelicobacter Infection+2 more

View study

UNKNOWNPHASE3

A Unique Regimen for Treatment of Helicobacter Pylori Infection

NCT03491995

Helicobacter Infections

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 7, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

Inclusion Criteria

Exclusion Criteria

Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

A Unique Regimen for Treatment of Helicobacter Pylori Infection

Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.